ERBB2 and breast cancer: The majority of breast cancer patients are diagnosed with luminal tumors that are characterized by the expression of estrogen receptors (ER) and progesterone receptors (PR) and the absence or only weak amplification of HER2 (this latter parameter depends on the subclass, whether luminal A or luminal B) [1, 2].